Welcome to LookChem.com Sign In|Join Free
  • or
(VAL671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-676) is a peptide compound derived from the amyloid beta (Aβ) protein precursor, which is crucial in the pathogenesis of Alzheimer's disease. This specific sequence of amino acids 667-676 has been recognized for its potential as a therapeutic target to disrupt the formation and accumulation of Aβ plaques in the brain. Targeting this region may prevent or decelerate the progression of Alzheimer's disease by inhibiting Aβ aggregation and reducing its neurotoxic effects, with ongoing research aimed at developing novel treatments based on (VAL671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-676).

252256-43-2

Post Buying Request

252256-43-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

252256-43-2 Usage

Uses

Used in Pharmaceutical Research and Development:
(VAL671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-676) is used as a target for therapeutic interventions in the development of treatments for Alzheimer's disease. It is employed to explore the inhibition of Aβ aggregation and the reduction of its neurotoxic effects, with the aim of preventing or slowing the disease's progression.
Used in Neuroscience and Neurodegenerative Disease Research:
In the field of neuroscience, particularly in the study of neurodegenerative diseases, (VAL671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-676) is used as a research tool to understand the molecular mechanisms underlying Alzheimer's disease. It aids in investigating the role of Aβ protein precursor in disease pathogenesis and the potential of this peptide sequence in developing therapeutic strategies.
Used in Drug Discovery and Design:
(VAL671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-676) is utilized in drug discovery and design processes to identify and optimize compounds that can effectively target the Aβ protein precursor. This is crucial for creating new drugs that may treat Alzheimer's disease by modulating the aggregation and toxicity of Aβ peptides.
Used in Clinical Trials for Alzheimer's Disease Treatments:
As a potential therapeutic target, (VAL671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-676) may be involved in clinical trials for Alzheimer's disease treatments. It serves as a basis for testing the efficacy and safety of new compounds designed to target this specific region of the Aβ protein precursor in human subjects.

Check Digit Verification of cas no

The CAS Registry Mumber 252256-43-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,2,2,5 and 6 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 252256-43:
(8*2)+(7*5)+(6*2)+(5*2)+(4*5)+(3*6)+(2*4)+(1*3)=122
122 % 10 = 2
So 252256-43-2 is a valid CAS Registry Number.

252256-43-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name (VAL671)-AMYLOID β/A4 PROTEIN PRECURSOR770 (667-676)

1.2 Other means of identification

Product number -
Other names [VAL671]-AMYLOID B/A4 PROTEIN PRECURSOR 770 FRAGMENT 667-676 TRIFLUOROACETATE SALT

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:252256-43-2 SDS

252256-43-2Upstream product

252256-43-2Downstream Products

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 252256-43-2